PERLMAN ANDREW J 4

What Happened Andrew J. Perlman, a director of Arcus Biosciences (RCUS), was granted compensation awards on 2026-06-11: 5,700 restricted stock units (RSUs) and a 16,900-share derivative award (an option-like award), both recorded at $0.00. These are awards (A) — not open-market purchases or sales — and reflect director compensation rather than an immediate market transaction.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
• Awards: 5,700 RSUs @ $0.00 (acquired); 16,900 derivative award @ $0.00 (acquired, reported as derivative).
• Shares owned after transaction: not specified in the filing.
• Footnotes:
  • F1: RSUs vest in full on the earlier of June 11, 2027 or the next annual meeting; immediate vesting on a change in control.
  • F2: The derivative award vests in full on the earlier of June 11, 2027 or the next annual meeting and becomes fully vested/exercisable on a change in control.
• No 10b5-1, tax-withholding, or sale information disclosed; no indication of a cash exercise or immediate sale.

Context RSUs represent a promise to receive shares upon vesting; the derivative award is an option-like grant that will become exercisable after vesting. Grants to directors are common as part of compensation packages and do not by themselves signal buying or selling intent in the open market.